News und Analysen
![Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?: https://g.foolcdn.com/editorial/images/749955/investor-considers-laptop-with-notebook.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMHV2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ac990fa355d26865cdf82c992fe65786f8fc3be6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-considers-laptop-with-notebook.jpg?locale=de)
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
On Oct. 1, Viatris (NASDAQ: VTRS) made an announcement that's sure to shake up its fortunes. It's divesting nearly all of its over-the-counter (OTC) medicines, its entire women's healthcare segment
![Could Viatris Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/748876/rich-person-standing-next-to-a-jet-and-convertible.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeStoYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e6c8734432fb7f8262ca5da8b8e050bf47bdf398/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/rich-person-standing-next-to-a-jet-and-convertible.jpg?locale=de)
Could Viatris Stock Help You Become a Millionaire?
If you're investing $25,000 in your stock portfolio, then getting that investment to be worth $1 million over time is no simple task. Odds are, you'll have to wait decades for that investment to
![Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks: https://g.foolcdn.com/editorial/images/747177/a-couple-counting-money.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFdSYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0b5fa16450ddf1773099e340a348828170a3fe29/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-couple-counting-money.jpg?locale=de)
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
Inflation is giving investors more of an incentive to find ways to increase their income. If you have a decent nest egg saved up, you can use it to invest in dividend stocks to improve your
![Viatris Stock: Bear vs. Bull: https://g.foolcdn.com/editorial/images/745483/two-investors-consider-a-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3FDYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1ccc0cc4deaa30a8b6e7f3f3c2816a28a86fb0ba/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-investors-consider-a-laptop.jpg?locale=de)
Viatris Stock: Bear vs. Bull
If you're wondering whether to buy Viatris (NASDAQ: VTRS) stock this fall, it's important to know the arguments for why it might gain value as well as why it's not the best option.
Generic drug
![LivaNova präsentiert Essenz In-Line Blood Monitor mit U.S. FDA 510(k)-Zulassung und CE-Prüfzeichen: https://mms.businesswire.com/media/20230830618951/de/1878567/5/LivaNova_Essenz_ILBM_image.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMDZDYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--feb8bc8b0638503cde2be2bf43454da322813781/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LivaNova_Essenz_ILBM_image.jpg?locale=de)
LivaNova präsentiert Essenz In-Line Blood Monitor mit U.S. FDA 510(k)-Zulassung und CE-Prüfzeichen
LivaNova PLC (Nasdaq: LIVN), ein Marktführer im Bereich der Medizintechnik, gab heute bekannt, dass es die 510(k)-Zulassung der US-amerikanischen Food and Drug Administration (FDA) und das
![LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark: https://mms.businesswire.com/media/20230830793488/en/1878567/5/LivaNova_Essenz_ILBM_image.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeXlDYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--86a19a32ba00e2661d09b9d517379e69f3ddf2c5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LivaNova_Essenz_ILBM_image.jpg?locale=de)
LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark for its Essenz™ In-Line
![Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris: https://g.foolcdn.com/editorial/images/745296/researcher.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3A5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7aae4cdfeff66f919db6a5986af5d443b0eef438/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/researcher.jpg?locale=de)
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS).
Both companies offer
![Where Will Viatris Be in 5 Years?: https://g.foolcdn.com/editorial/images/744167/pharmacist-helping-someone-with-a-prescription.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeHgzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ead52e031b5533c70aaba0519f5bc9873afcd807/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/pharmacist-helping-someone-with-a-prescription.jpg?locale=de)
Where Will Viatris Be in 5 Years?
Viatris (NASDAQ: VTRS) hasn't made for a particularly great investment since it formed nearly three years ago, through a merger of Mylan and Pfizer's Upjohn business. Down 29% since then, it has
![Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?: https://g.foolcdn.com/editorial/images/744131/pharmacist-consults-tablet-in-pharmacy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd2wxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4d8d28d1ec928d939d00a99806f2f24486c51dc7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/pharmacist-consults-tablet-in-pharmacy.jpg?locale=de)
Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?
Viatris (NASDAQ: VTRS) could be on the verge of eating the lunch of Novo Nordisk's (NYSE: NVO) two golden cash cows: The diabetes drug Ozempic, and another version that's formulated for weight loss
![2 Beaten-Down Dividend Stocks to Buy: https://g.foolcdn.com/editorial/images/743231/doctor-with-patient-talking.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1J3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--588e5a03ccf4aafe08c71fd3945d83cbdbfdef20/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-with-patient-talking.jpg?locale=de)
2 Beaten-Down Dividend Stocks to Buy
Dividend stocks can be great additions to anyone's portfolio, and it's even better to buy quality ones when they're down. While the market has roared back this year following a downturn in 2022, it
![If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today: https://g.foolcdn.com/editorial/images/742976/investor-pointing-at-a-chart.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMVJ3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4368b5756d97d38ebad5556ce81bb63dfabc2829/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-pointing-at-a-chart.jpg?locale=de)
If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today
Viatris (NASDAQ: VTRS) spun off from Pfizer and merged with Mylan back in 2020. It's a generic drugmaker with a diverse, global business that serves patients and customers in over 165 countries and
![Is Viatris Stock Good for Dividend Income?: https://g.foolcdn.com/editorial/images/743056/investor-considers-papers-at-a-cafe.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM050YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--bc4a1d89b8596a596ba0fd32795bcc7a309c8167/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-considers-papers-at-a-cafe.jpg?locale=de)
Is Viatris Stock Good for Dividend Income?
Viatris (NASDAQ: VTRS) is a stock of immense interest among the dividend investing community, and it's no surprise why. Generic drugmakers, when operating smoothly, can be veritable cash machines
![Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years: https://g.foolcdn.com/editorial/images/742230/investors-smile-as-one-signs-a-contract.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMWxvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ce690940cbc18c7faf816ebacb06aaeab623037c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investors-smile-as-one-signs-a-contract.jpg?locale=de)
Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years
Especially if you're living on a fixed income, being able to bring in even $1,500 in extra money each year via dividends can be a big change for the better. But it's often difficult to figure out
![Viatris Stock: Bull vs. Bear: https://g.foolcdn.com/editorial/images/740374/gettyimages-scientists-in-lab02.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3RYYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e2fa90e17c39e96daeaba62fb8c6ac0617893230/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-scientists-in-lab02.jpg?locale=de)
Viatris Stock: Bull vs. Bear
Even if you don't recognize the name Viatris (NASDAQ: VTRS), you may have come in very close contact with this pharma company. It sells a wide variety of generic drugs -- such as generic Zyrtec
![1 Reason I Wouldn't Buy This High-Yielding Dividend Stock: https://g.foolcdn.com/editorial/images/739959/a-person-sitting-with-their-child-looking-at-a-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNmRWYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1a124f1327508ee120a78c6e9727b9c955f2fa26/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-person-sitting-with-their-child-looking-at-a-laptop.jpg?locale=de)
1 Reason I Wouldn't Buy This High-Yielding Dividend Stock
A high-yielding dividend stock can generate lots of dividend income for your portfolio. But that doesn't mean you should buy a stock only because of its yield. Dividends are never guaranteed and
![Better Pharma Buy: Viatris vs. Pfizer: https://g.foolcdn.com/editorial/images/740301/gettyimages-women-investors.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMWhVYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--220344efdf8471a866d4b2c39040e96be82153cb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-women-investors.jpg?locale=de)
Better Pharma Buy: Viatris vs. Pfizer
Pfizer (NYSE: PFE) and Viatris (NASDAQ: VTRS) have a common past. That's because Viatris came about a few years ago when Pfizer's Upjohn business merged with generic drug giant, Mylan. Since, their
![Why Amarin Stock Is Sinking Today: https://g.foolcdn.com/editorial/images/740399/downsizing.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenBVYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dd31d81f494a5c3414c0903e1d69d3364b3746d0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/downsizing.jpg?locale=de)
Why Amarin Stock Is Sinking Today
Shares of Amarin (NASDAQ: AMRN) were sinking 22.7% as of 10:56 a.m. ET on Wednesday. The steep decline came after the drugmaker announced an organizational restructuring after the market close on
![Better High-Yield Dividend Stock: Altria or Viatris?: https://g.foolcdn.com/editorial/images/739969/dividends.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOUJQYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7a6cad1dba0bfeeeda7221d75d3ba22dc4bd3e6d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dividends.jpg?locale=de)
Better High-Yield Dividend Stock: Altria or Viatris?
If you are looking for a high-yield dividend stock to boost your income, you might be interested in Altria (NYSE: MO) or Viatris (NASDAQ: VTRS). Both companies offer attractive dividend yields of
![3 Reasons to Buy Viatris Stock, and 1 Reason to Sell: https://g.foolcdn.com/editorial/images/739304/team-of-medical-experts-talking-on-a-meeting-at-doctors-office.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFJPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--64c0d096bbc55372efdbb7ed21e4c1a67d4ff592/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/team-of-medical-experts-talking-on-a-meeting-at-doctors-office.jpg?locale=de)
3 Reasons to Buy Viatris Stock, and 1 Reason to Sell
Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof
![Wall Street Thinks Viatris Stock Will Rise 25% -- Could It Grow Even More?: https://g.foolcdn.com/editorial/images/738452/investor-stands-in-kitchen-considering-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzVEYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0aedf0460c35e4cdaced95c51ab3488c4ee294e5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-stands-in-kitchen-considering-laptop.jpg?locale=de)
Wall Street Thinks Viatris Stock Will Rise 25% -- Could It Grow Even More?
For a generic drugmaker like Viatris (NASDAQ: VTRS), big spurts of growth are unlikely. The market for low-cost generic medications is competitive, and success is largely defined by maintaining
![Why Shares of Abcam Are Jumping Friday: https://g.foolcdn.com/editorial/images/737414/healthcare-lab-treatment-research-scientist-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMG82YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--84cdfd406fd316bebf0e049a77403a7364a80713/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/healthcare-lab-treatment-research-scientist-1.jpg?locale=de)
Why Shares of Abcam Are Jumping Friday
Shares of life sciences company Abcam (NASDAQ: ABCM) were up 13.7% Friday afternoon after rising more than 14.6% earlier in the day. The impetus for the rise was the company's board of directors
![Why Shares in Abcam Surged This Week: https://g.foolcdn.com/editorial/images/736489/plan-ahead-sign.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOVF4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2fb6c577437a6a74c87a3a960ad675b5dee3fdee/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/plan-ahead-sign.jpg?locale=de)
Why Shares in Abcam Surged This Week
Shares in UK-based life sciences company Abcam (NASDAQ: ABCM) were up 12.7% in the week at 11 a.m. ET. The move comes in an exciting week of news for the company, involving an unhappy founder, a
![These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys: https://g.foolcdn.com/editorial/images/735027/a-couple-reviewing-a-statement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2NwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--103827aa67bdf4171dd1e1b391816c7491f5b037/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-couple-reviewing-a-statement.jpg?locale=de)
These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys
You can secure a 5% dividend yield without being too risky or aggressive. Sometimes, it's a matter of jumping on a good opportunity when it arises. A stock can fall in value for various reasons
![It's Cheap and Pays a Big Dividend, But Is Viatris Stock a Buy?: https://g.foolcdn.com/editorial/images/732730/three-investors-meet-with-paperwork.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODhSYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--05bb944f2d886fae0c18acf9ef5620c14c4bbd9c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/three-investors-meet-with-paperwork.jpg?locale=de)
It's Cheap and Pays a Big Dividend, But Is Viatris Stock a Buy?
Companies that produce generic drugs aren't known for being exciting investments, and there's little chance they'll ever expand as fast as your average tech stock or most other growth stocks. If
![Amarin Plc (AMRN) Q1 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=de)
Amarin Plc (AMRN) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
Amarin Plc (NASDAQ: AMRN)Q1 2023 Earnings CallMay 03, 2023, 8:00 a.m. ET
Operator
Source Fool.com